| 1 |
Miller DT, Freedenberg D, Schorry E, Ullrich NJ, Viskochil D, Korf BR, et al. Health supervision for children with neurofibromatosis type 1. Pediatrics 2019;143:e20190660.
DOI
|
| 2 |
Viskochil D. Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol 2002;17:562-651.
DOI
|
| 3 |
Armstrong AE, Brossier NM, Hirbe AC. Neurofibromatosis type 1-related tumours in paediatrics: an evolving treatment landscape. Lancet Child Adolesc Health 2020;4:488-90.
DOI
|
| 4 |
Allaway RJ, Gosline SJC, La Rosa S, Knight P, Bakker A, Guinney J, et al. Cutaneous neurofibromas in the genomics era: current understanding and open questions. Br J Cancer 2018;118:1539-48.
DOI
|
| 5 |
Wu-Chou YH, Hung TC, Lin YT, Cheng HW, Lin JL, Lin CH, et al. Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis. J Biomed Sci 2018;25:72.
DOI
|
| 6 |
Killock D. Selumetinib benefits children with inoperable plexiform neurofibromas. Nat Rev Clin Oncol 2020;17:273.
DOI
|
| 7 |
Ly KI, Blakeley JO. The diagnosis and management of neurofibromatosis type 1. Med Clin North Am 2019;103:1035-54.
DOI
|
| 8 |
Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007;44:81-8.
DOI
|
| 9 |
Kang EG, Yoon HM, Lee BH. Neurofibromatosis type I: points to be considered by general pediatricians. Clin Exp Pediatr 2021;64:149-56. https://doi.org/10.3345/cep.2020.00871.
DOI
|
| 10 |
Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med 2020;382:1430-42.
DOI
|
webmaster
